In the days of the Armada, a fleet of warships, the scuttlebutt was the rumor or gossip that would spread throughout the ship. Today, Armada Law Corp presents The Scuttlebutt, a daily summery of news articles that people within the cannabis, hemp and plant medicine industries are chatting about along with links to the full articles.
In today’s news:
#psychedelicresearch – “Researchers at the Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute at the Cleveland Clinic in Ohio have authored a case report on the positive effects of psilocybin on color blindness….
The researchers suggest it is likely that psychedelic-induced visual phenomena result primarily from alterations in brain activity
rather than their direct effects on the retina and peripheral eye. Based on the time delay between psilocybin and color vision, the mushroom may have catalyzed a learning process around color interpretation, possibly altering the connectivity between visual regions.”
#psychedelics – “We do have to vet the clients before they’re able to receive any services. And within Measure 109
, a lot of those things are already predetermined. We’re supposed to be screening out certain conditions. If a person, for example, has been taking lithium within the last three months, they would not be suited to take this medication, because of the concerns of physiological harm. A lot of things are going to be up to the facilitator to determine whether they feel like there’s an affinity, if they’re going to be able to support the clients adequately.
Preparing for the possibly adverse effects within a trip is going to be really reliant on the relationship between the facilitator and the client. A lot of it is going to be between the preparation sessions and the intentions and the set and setting that we’re able to create. But some of it is going to be just a surprise. There is no guarantee of a particular type of trip. Sometimes the experience might turn a bit unpleasant. Hopefully, the facilitator is able to support the client to regulating themselves and find value and virtue within their experience anyways.”
#cannabisindustry – “National Basketball Association (NBA) players will not be able to promote marijuana companies under a new collective bargaining agreement, contrary to early reports about the deal with the players union
, a new summary document shows. But the league will remove drug testing requirements for THC, while allowing players to passively invest in the industry.
The document stipulates that while players “may promote a company that makes products containing CBD,” they will “continue to be prohibited from promoting marijuana companies.””
#cannabisindustry – “Maryland Gov. Wes Moore on Wednesday signed into law a bill to launch regulated sales of adult-use marijuana beginning in July and tax them at a 9% rate, following voters’ overwhelming approval of legalization on Election Day, Nov. 8, 2022.
Maryland’s adult-use legalization ballot measure, Question 4, passed with 67% of the vote. But other than including an effective date of July, the constitutional amendment had few details about how the market would be regulated.”
#cannabisindustry – “Starting in 2025, Kentuckians will be able to apply for a medical marijuana card after obtaining a written certification from their medical practitioner showing a qualified medical condition. Those conditions are as follows:
- Any type or form of cancer regardless of stage;
- Chronic, severe, intractable, or debilitating pain;
- Epilepsy or any other intractable seizure disorder;
- Multiple sclerosis, muscle spasms, or spasticity;
- Chronic nausea or cyclical vomiting syndrome that has proven resistant to other conventional medical treatments;
- Post-traumatic stress disorder; and
- Any other medical condition or disease for which the Kentucky Center for Cannabis established in KRS 164.983, or its successor, determines that sufficient scientific data and evidence exists to demonstrate that an individual diagnosed with that condition or disease is likely to receive medical, therapeutic, or palliative benefits from the use of medicinal cannabis.”